Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

▤ Summary

Alphyn Biologics closed an oversubscribed $25 million Series B round to advance its dermatology pipeline. The company will use the money to fund a global Phase 2b trial for Zabalafin Hydrogel in atopic dermatitis and start a Phase 2 program in molluscum contagiosum. The round included both new and existing investors, led by QCA Investment Group. Alphyn says the financing supports its path toward Phase 3 trials and broader development of its skin-disease therapies.

$ Funding

▦ Linked Companies